Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-395-2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$77.35 million
Profitability
Miscellaneous
Employees255
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Recro Pharma (NASDAQ:REPH) Frequently Asked Questions
What is Recro Pharma's stock symbol?
Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."
How were Recro Pharma's earnings last quarter?
Recro Pharma Inc (NASDAQ:REPH) announced its quarterly earnings data on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.29. The specialty pharmaceutical company earned $31.26 million during the quarter, compared to the consensus estimate of $24.06 million. View Recro Pharma's Earnings History.
When is Recro Pharma's next earnings date?
What guidance has Recro Pharma issued on next quarter's earnings?
Recro Pharma issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $91-94 million, compared to the consensus revenue estimate of $91.33 million.
What price target have analysts set for REPH?
5 analysts have issued 1-year price targets for Recro Pharma's stock. Their forecasts range from $7.50 to $20.00. On average, they expect Recro Pharma's stock price to reach $12.90 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Recro Pharma.
What is the consensus analysts' recommendation for Recro Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.
Has Recro Pharma been receiving favorable news coverage?
Headlines about REPH stock have been trending somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Recro Pharma earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Recro Pharma.
Are investors shorting Recro Pharma?
Recro Pharma saw a decline in short interest in September. As of September 30th, there was short interest totalling 772,600 shares, a decline of 19.7% from the August 30th total of 962,700 shares. Based on an average daily volume of 180,500 shares, the days-to-cover ratio is currently 4.3 days. Approximately 4.1% of the shares of the company are short sold. View Recro Pharma's Current Options Chain.
Who are some of Recro Pharma's key competitors?
Some companies that are related to Recro Pharma include ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Odonate Therapeutics (ODT), AnaptysBio (ANAB), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), ZEALAND PHARMA/S (ZEAL) and Eagle Pharmaceuticals (EGRX).
What other stocks do shareholders of Recro Pharma own?
Who are Recro Pharma's key executives?
Recro Pharma's management team includes the folowing people:
- Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
- Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
- Mr. Michael Celano, COO & Corp. Sec. (Age 60)
- Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
- Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)
Who are Recro Pharma's major shareholders?
Recro Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bowling Portfolio Management LLC (0.17%) and Meeder Asset Management Inc. (0.05%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood, Healthcare Master Fun Broadfin, Scp Vitalife Partners (Israel) and Scp Vitalife Partners Ii Lp. View Institutional Ownership Trends for Recro Pharma.
Which major investors are selling Recro Pharma stock?
Which major investors are buying Recro Pharma stock?
How do I buy shares of Recro Pharma?
Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Recro Pharma's stock price today?
One share of REPH stock can currently be purchased for approximately $12.12.
How big of a company is Recro Pharma?
Recro Pharma has a market capitalization of $271.83 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.
What is Recro Pharma's official website?
How can I contact Recro Pharma?
Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2400 or via email at [email protected]
MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
